Immuno‐Oncology Biomarkers for Gastric and Gastroesophageal Junction Adenocarcinoma: Why PD‐L1 Testing May Not Be Enough

Purpose The treatment of patients with advanced gastric and gastroesophageal junction (G/GEJ) adenocarcinomas has been transformed by the U.S. Food and Drug Administration approval of pembrolizumab. Tumor and adjacent tissue must stain positively for the programmed cell death ligand 1 (PD‐L1) protei...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	The oncologist (Dayton, Ohio) Ohio), 2018-10, Vol.23 (10), p.1171-1177
Hauptverfasser:	Weinberg, Benjamin A., Xiu, Joanne, Hwang, Jimmy J., Shields, Anthony F., Salem, Mohamed E., Marshall, John L.
Format:	Artikel
Sprache:	eng
Schlagworte:	Checkpoint inhibitor Gastric adenocarcinoma Gastroesophageal adenocarcinoma Gastrointestinal Cancer Immunotherapy Programmed death ligand 1
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!